Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R C F Leonard

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
Journal of Clinical Pathology|March 29, 2003
Type 1 growth factor receptor expression in node positive breast cancer: adverse prognostic significance of c-erbB-4A J Lodge, J J Anderson, W J Gullick, et al.
British Journal of Cancer|December 13, 2006
Quality of life and sexual function after high-dose or conventional chemotherapy for high-risk breast cancerK M Malinovszky, A Gould, E Foster, et al.
Molecular Pathology : MP|May 29, 2002
Limitations of the use of single base changes in the p53 gene to detect minimal residual disease of breast cancerR K B Dang, R S Anthony, J I O Craig, et al.
Anticancer Research|April 12, 2003
Is there a relationship between HLA type and prognostic factors in breast cancer?C Gourley, C Thornton, C Massie, et al.
Breast (Edinburgh, Scotland)|September 30, 2004
Breast cancer patients' experiences on endocrine therapy: monitoring with a checklist for patients on endocrine therapy (C-PET)K M Malinovszky, D Cameron, S Douglas, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 30, 2015
A randomised trial of secondary prophylaxis using granulocyte colony-stimulating factor ('SPROG' trial) for maintaining dose intensity of standard adjuvant chemotherapy for breast cancer by the Anglo-Celtic Cooperative Group and NCRNR C F Leonard, J L Mansi, C Keerie, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 5, 2017
GnRH agonist for protection against ovarian toxicity during chemotherapy for early breast cancer: the Anglo Celtic Group OPTION trialR C F Leonard, D J A Adamson, G Bertelli, et al.
British Journal of Cancer|November 28, 2002
Block sequential adriamycin CMF--optimal non-myeloablative chemotherapy for high risk adjuvant breast cancer?D A Cameron, A Anderson, E Toy, et al.
British Journal of Cancer|October 11, 2012
Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer: results with over 7 years median follow-up from the randomised phase III NEAT/BR9601 trialsH M Earl, L Hiller, J A Dunn, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Journal of Clinical Pathology|March 29, 2003
Type 1 growth factor receptor expression in node positive breast cancer: adverse prognostic significance of c-erbB-4A J Lodge, J J Anderson, W J Gullick, et al.
British Journal of Cancer|December 13, 2006
Quality of life and sexual function after high-dose or conventional chemotherapy for high-risk breast cancerK M Malinovszky, A Gould, E Foster, et al.
Molecular Pathology : MP|May 29, 2002
Limitations of the use of single base changes in the p53 gene to detect minimal residual disease of breast cancerR K B Dang, R S Anthony, J I O Craig, et al.
Anticancer Research|April 12, 2003
Is there a relationship between HLA type and prognostic factors in breast cancer?C Gourley, C Thornton, C Massie, et al.
Breast (Edinburgh, Scotland)|September 30, 2004
Breast cancer patients' experiences on endocrine therapy: monitoring with a checklist for patients on endocrine therapy (C-PET)K M Malinovszky, D Cameron, S Douglas, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 30, 2015
A randomised trial of secondary prophylaxis using granulocyte colony-stimulating factor ('SPROG' trial) for maintaining dose intensity of standard adjuvant chemotherapy for breast cancer by the Anglo-Celtic Cooperative Group and NCRNR C F Leonard, J L Mansi, C Keerie, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 5, 2017
GnRH agonist for protection against ovarian toxicity during chemotherapy for early breast cancer: the Anglo Celtic Group OPTION trialR C F Leonard, D J A Adamson, G Bertelli, et al.
British Journal of Cancer|November 28, 2002
Block sequential adriamycin CMF--optimal non-myeloablative chemotherapy for high risk adjuvant breast cancer?D A Cameron, A Anderson, E Toy, et al.
British Journal of Cancer|October 11, 2012
Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer: results with over 7 years median follow-up from the randomised phase III NEAT/BR9601 trialsH M Earl, L Hiller, J A Dunn, et al.
Pageof 2